Biodegradable Polymer Versus Polymer-Free Ultrathin Sirolimus-Eluting Stents: Analysis of the Stent Arm Registry From the HOST-IDEA Randomized Trial
Circulation: Cardiovascular Interventions · 2024
DOI: 10.1161/circinterventions.123.013585 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Circulation: Cardiovascular Interventions, 2024. Verfasst von Jung-Kyu Han und 20 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Center, Seoul National University Hospital, Republic of Korea (J.-K.H., S. Yang, D.H., S.-H. Park, J. Kang, H.-M. Yang, K.W. Park, H.-…. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Percutaneous Coronary Intervention, Registries, Prosthesis Design. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The efficacy and safety of each third-generation drug-eluting stent with ultrathin struts and advanced polymer technology remain unclear. We investigated the clinical outcomes of percutaneous coronary intervention using the Coroflex ISAR polymer-free sirolimus-eluting stent (SES) or Orsiro biodegradable polymer SES. METHODS: The HOST-IDEA trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–Coronary Intervention With Next-Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy), initially designed with a 2×2 factorial approach, sought to randomize patients undergoing percutaneous coronary intervention based on dual antiplatelet therapy duration (3 versus 12 months) and stent type (Coroflex ISAR versus Orsiro). Despite randomizing 2013 patients for dual antiplatelet therapy duration, the stent arm transitioned to a registry format during the trial. Among these, 328 individuals (16.3%) were randomized for Coroflex ISAR or Orsiro SES, while 1685 (83.7%) underwent percutaneous coronary intervention without stent-type randomization. In this study, the Coroflex ISAR (n=559) and Orsiro groups (n=1449) were matched using a propensity score. The prespecified primary end point was target lesion failure, a composite of cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization at 12 months. RESULTS: The baseline patient and procedural characteristics were well balanced between the Coroflex ISAR and Orsiro groups after propensity score matching (n=559, each group). The Coroflex ISAR group was significantly associated with a higher rate of target lesion failure, mainly driven by clinically driven target lesion revascularization, compared with the Orsiro group (3.4% versus 1.1%; hazard ratio, 3.21 [95% CI, 1.28–8.05]; P =0.01). A higher risk of target lesion failure in the Coroflex ISAR group was consistently observed across various subgroups. The rates of any bleeding (hazard ratio, 0.85 [95% CI, 0.51–1.40]; P =0.52) and major bleeding (hazard ratio, 1.58 [95% CI, 0.61–4.08]; P =0.34) were comparable between the 2 groups. CONCLUSIONS: In this propensity score-matched analysis of the stent arm registry from the HOST-IDEA trial, the Orsiro SES was associated with significantly better outcomes in terms of 1-year target lesion failure, mainly driven by clinically driven target lesion revascularization, than the Coroflex ISAR SES. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02601157.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Center, Seoul National University Hospital, Republic of Korea (J.-K.H., S. Yang, D.H., S.-H. Park, J. Kang, H.-M. Yang, K.W. Park, H.-J. Kang, B.-K.K., H.-S. Kim).
- Department of Internal Medicine, College of Medicine, Seoul National University, Republic of Korea (J.-K.H., H.-M. Yang, K.W. Park, H.-J. Kang, B.-K.K., H.-S. Kim).
- Cardiovascular Center, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea (J.-M. Cho).
- Department of Cardiology, Heart Center, Saint Carollo Hospital, Sun-cheon, Republic of Korea (J. Cho).
- Division of Cardiology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea (D.W.B.).
- Division of Cardiology, Department of Internal Medicine, Chungnam National University Sejong Hospital, Chungnam National University School of Medicine, Republic of Korea (J.-H. Lee).
ORCID-Profile: Jung-Kyu Han, Seokhun Yang, Han-Mo Yang, Kyung Woo Park, Hyun-Jae Kang, Bon-Kwon Koo, Jin-Man Cho, Janghyun Cho, Jae-Hwan Lee, Kyung-Jin Kim, Sang Min Park, Jin Won Kim, Hyo-Soo Kim
Zitieren
APA
Han, J. K., Yang, S., Hwang, D., Park, S. H., Kang, J., Yang, H. M., Park, K. W., Kang, H. J., Koo, B. K., Cho, J. M., Cho, J., Bang, D. W., Lee, J. H., Lee, H. C., Kim, K. J., Chun, W. J., Seo, W. W., Park, W. J., Park, S. M., …, & Kim, H. S. (2024). Biodegradable Polymer Versus Polymer-Free Ultrathin Sirolimus-Eluting Stents: Analysis of the Stent Arm Registry From the HOST-IDEA Randomized Trial. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.123.013585
Vancouver
Han JK, Yang S, Hwang D, Park SH, Kang J, Yang HM, et al. Biodegradable Polymer Versus Polymer-Free Ultrathin Sirolimus-Eluting Stents: Analysis of the Stent Arm Registry From the HOST-IDEA Randomized Trial. Circulation: Cardiovascular Interventions. 2024. doi:10.1161/circinterventions.123.013585
BibTeX
@article{Han2024,
author = {Han, Jung-Kyu and Yang, Seokhun and Hwang, Doyeon and Park, Sang-Hyeon and Kang, Jeehoon and Yang, Han-Mo and Park, Kyung Woo and Kang, Hyun-Jae and Koo, Bon-Kwon and Cho, Jin-Man and Cho, Janghyun and Bang, Duk Won and Lee, Jae-Hwan and Lee, Han Cheol and Kim, Kyung-Jin and Chun, Woo Jung and Seo, Won-Woo and Park, Woo-Jung and Park, Sang Min and Kim, Jin Won and Kim, Hyo-Soo},
title = {Biodegradable Polymer Versus Polymer-Free Ultrathin Sirolimus-Eluting Stents: Analysis of the Stent Arm Registry From the HOST-IDEA Randomized Trial},
journal = {Circulation: Cardiovascular Interventions},
year = {2024},
doi = {10.1161/circinterventions.123.013585}
}
EUVIMED